Free Trial

Banco Santander S.A. Has $1.35 Million Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Ocular Therapeutix logo with Medical background

Key Points

  • Banco Santander S.A. increased its holdings in Ocular Therapeutix by 21.8% in the first quarter, owning 184,048 shares valued at $1.35 million as of its most recent SEC filing.
  • Ocular Therapeutix's stock price was up 2.9%, trading at $11.92, and the company has a market capitalization of $1.90 billion with a 52-week range of $5.78 to $12.35.
  • Analysts have a consensus "Buy" rating for Ocular Therapeutix, with an average price target of $17.33.
  • MarketBeat previews the top five stocks to own by September 1st.

Banco Santander S.A. grew its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 21.8% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 184,048 shares of the biopharmaceutical company's stock after acquiring an additional 32,941 shares during the quarter. Banco Santander S.A. owned 0.12% of Ocular Therapeutix worth $1,349,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of OCUL. MetLife Investment Management LLC raised its stake in Ocular Therapeutix by 2.7% during the 4th quarter. MetLife Investment Management LLC now owns 92,734 shares of the biopharmaceutical company's stock valued at $792,000 after purchasing an additional 2,454 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Ocular Therapeutix by 3.3% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,463 shares of the biopharmaceutical company's stock worth $755,000 after purchasing an additional 2,853 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Ocular Therapeutix during the fourth quarter valued at about $28,000. Cetera Investment Advisers lifted its stake in shares of Ocular Therapeutix by 0.6% in the fourth quarter. Cetera Investment Advisers now owns 723,840 shares of the biopharmaceutical company's stock valued at $6,182,000 after buying an additional 4,342 shares during the period. Finally, Wellington Management Group LLP lifted its stake in shares of Ocular Therapeutix by 1.0% in the fourth quarter. Wellington Management Group LLP now owns 467,352 shares of the biopharmaceutical company's stock valued at $3,991,000 after buying an additional 4,488 shares during the period. Institutional investors and hedge funds own 59.21% of the company's stock.

Ocular Therapeutix Stock Up 2.9%

Shares of NASDAQ:OCUL opened at $11.92 on Monday. The company has a 50 day moving average price of $9.71 and a two-hundred day moving average price of $8.23. The company has a debt-to-equity ratio of 0.26, a quick ratio of 10.14 and a current ratio of 10.22. The company has a market capitalization of $1.90 billion, a PE ratio of -10.37 and a beta of 1.49. Ocular Therapeutix, Inc. has a 52 week low of $5.78 and a 52 week high of $12.35.

Insider Transactions at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,219 shares of the firm's stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $7.18, for a total transaction of $152,352.42. Following the sale, the insider owned 3,499,099 shares of the company's stock, valued at $25,123,530.82. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Richard L. Md Lindstrom acquired 10,000 shares of the firm's stock in a transaction that occurred on Thursday, May 8th. The stock was acquired at an average price of $6.96 per share, with a total value of $69,600.00. Following the completion of the transaction, the director directly owned 172,704 shares in the company, valued at $1,202,019.84. This trade represents a 6.15% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders sold 29,079 shares of company stock valued at $208,739. Insiders own 2.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on OCUL shares. Needham & Company LLC lowered their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research report on Thursday, May 29th. Finally, William Blair assumed coverage on Ocular Therapeutix in a research report on Tuesday, April 8th. They issued an "outperform" rating for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $17.33.

View Our Latest Analysis on Ocular Therapeutix

Ocular Therapeutix Profile

(Free Report)

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Further Reading

Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report).

Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Ocular Therapeutix Right Now?

Before you consider Ocular Therapeutix, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocular Therapeutix wasn't on the list.

While Ocular Therapeutix currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines